CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.
暂无分享,去创建一个
A. Hofman | J. Coebergh | E. Berns | R. V. van Schaik | C. van Noord | B. Stricker | L. Visser | R. Ruiter | M. Bijl | A. Hofman | Monique J. Bijl
[1] B. Bonanni,et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial , 2011, The Pharmacogenomics Journal.
[2] Hein Putter,et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Newman,et al. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment , 2010, Pharmaceuticals.
[4] B. Stricker,et al. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies , 2010, European Journal of Epidemiology.
[5] Yusuke Nakamura,et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Goetz,et al. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen , 2010, Cancer.
[7] S. Sleijfer,et al. CYP-2C19*2Predicts Favorable Outcome of Tamoxifen Treatment for Advanced Breast Cancer. , 2009 .
[8] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[9] H. Sørensen,et al. Genotype-guided tamoxifen therapy: time to pause for reflection? , 2009, The Lancet. Oncology.
[10] D. Hochstrasser,et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.
[11] C. V. D. van de Velde,et al. Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.
[12] Monique M. B. Breteler,et al. The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.
[13] C. Alonso,et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment , 2009, Breast Cancer Research and Treatment.
[14] H. Brauch,et al. CYP2C19*17 is associated with decreased breast cancer risk , 2009, Breast Cancer Research and Treatment.
[15] A. Hofman,et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.
[16] D. Evans,et al. Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients , 2008, Clinical Cancer Research.
[17] S. Shi,et al. Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.
[18] Sabine Siesling,et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.
[19] Wolfgang Simon,et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Wingren,et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.
[21] Zeruesenay Desta,et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.
[22] David A. Flockhart,et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.
[23] Fergus J Couch,et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[25] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[26] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[27] J. Scheys,et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.
[28] T. Skaar,et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen , 2005, Cancer Chemotherapy and Pharmacology.
[29] L. Skoog,et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.
[30] David A. Flockhart,et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[31] T. Skaar,et al. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.
[32] A. Hofman,et al. Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.
[33] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[34] K. Turteltaub,et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. , 2002, Carcinogenesis.
[35] E. Gillam,et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[36] M. Eichelbaum,et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.
[37] J. Jonkman,et al. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19 , 2001, European Journal of Clinical Pharmacology.
[38] S. Dehal,et al. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.
[39] G. Tucker,et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. , 1997, Biochemical pharmacology.
[40] M. Rowlands,et al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[41] P. Ueland,et al. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.
[42] M. Kimmel,et al. Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes: High Recurrence Rates in the Postmenopausal Estrogen Receptor—Negative Group , 1987 .
[43] V. Jordan,et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.